The fundamentals and practice of docosahexaenoic acid therapy in peroxisomal disorders

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 3, Issue 2, 2000, Pages 101-108

  Martinez, Manuela ^a  

^a Maternity Children's Hospital   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID;

DIET THERAPY; DIETARY INTAKE; FAT INTAKE; HUMAN; PEROXISOME; REVIEW; ZELLWEGER SYNDROME;

EID: 0033928650     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075197-200003000-00004     Document Type: Review

References (77)

1. Rhodin J. Correlation of ultrastructural organization and function in normal and experimentally changed proximal convoluted tubule cells of the mouse kidney. PhD thesis. Stockholm, Sweden: Karolinska Institute; 1954.
2. de Duve C, Baudhuin P. Peroxisomes (microbodies and related particles). Physiol Rev 1966; 46:323-357.
3. Goldfischer S, Moore CL, Johnson AB, Spiro AJ, Valsmis MP, Wisniewski HK, et al. Peroxisomal and mitochondrial defects in the cerebro-hepato-renal syndrome. Science 1973; 182:62-64.
4. Lazarow PB, Moser HW. Disorders of peroxisome biogenesis. In: The metabolic basis of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D (editors). 7th CD-ROM edition. New York: McGraw-Hill; 1997. Records 38247-38973.
5. Bowen P, Lee CSN, Zellweger H, Lindenberg R. A familial syndrome of multiple congenital defects. Bull Johns Hopkins Hosp 1964; 114:402-414.
6. Opitz JM, Zu Rhein GM, Vitale L, Shahidi NT, Howe JJ, Chon SM, et al. The Zellweger syndrome (cerebrohepatorenal syndrome). Birth Defects Orig Art Ser 1969; 2:144-160.
7. Ulrich J, Hershkowitz N, Heits P, Sigrist T, Baerlocher P. Adrenoleukodystrophy: preliminary report of a connatal case, light-and electron microscopical, immunohistochemical and biochemical findings. Acta Neuropathol (Berl) 1978; 43:77-83.
8. Kelley RI, Datta NS, Dobyns WB, Hajra AK, Moser AB, Noetzel MJ, et al. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal poly dystrophy syndromes. Am J Med Genet 1986; 23:869-901.
9. Scotto JM, Hadchouel M, Odievre M, Laudat MH, Saudubray JM, Dulac O, et al. Infantile phytanic acid storage disease: a possible variant of Refsum's disease: three cases, including ultrastructural studies of the liver. J Inherit Metab Dis 1982; 5:83-90.
10. Poll-The BT, Saudubray JM, Ogier H, Schutgens RBH, Wanders RJA, Schrakamp G, et al. Infantile Refsum's disease: biochemical findings suggesting multiple peroxisomal dysfunction. J Inherit Metab Dis 1986; 9:169-174.
11. Powers JM, Moser HW. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol 1998; 8:101-120.
12. Moser AE, Singh I, Brown FR III, Solish GI, Kelley RI, Benke PJ, Moser HW. The cerebro-hepato-renal (Zellweger) syndrome: increased levels and impaired degradation of very long chain fatty acids, their use in prenatal diagnosis. N Engl J Med 1984; 310:1141-1146.
13. Bakkeren JA, Monnens LA, Trijbels JM, Maas JM. Serum very long chain fatty acid pattern in Zellweger syndrome. Clin Chim Acta 1984; 138:325-331.
14. Poulos A, Singh H, Paton B, Sharp P, Derwas N. Accumulation and defective β-oxidation of very long chain fatty acids in Zellweger's syndrome, adrenoleukodystrophy and Refsum's disease variants. Clin Genet 1986; 29:397-408.
15. Suzuki Y, Orii T, Mori M, Tatibana M, Hashimoto T. Deficient activities and proteins of peroxisomal β-oxidation enzymes in infants with Zellweger syndrome. Clin Chim Acta 1986; 156:191-196.
16. Wanders RJA, van Roermund CWT, van Wijland MJA, Heikoop J, Schutgens RBH, Schram AW, et al. Peroxisomal very long chain fatty acid β-oxidation in human skin fibroblasts: activity in Zellweger syndrome and other peroxisomal disorders. Clin Chim Acta 1987; 166:255-263.
17. Hajra AK, Burke CL, Jones CL. Subcellular localization of acyl-coenzyme A: dihydroxyacetone phosphate acyltransferase in rat liver peroxisomes (microbodies). J Biol Chem 1979; 254:10896-10900.
18. Hajra AK, Bishop JE. Glycerolipid biosynthesis in peroxisomes via de acyl dihydroxyacetone phosphate pathway. Ann NY Acad Sci 1982; 386:170-182.
19. Heymans HSA, Schutgens RBH, Tan R, van den Bosch H, Borst P. Severe plasmalogen deficiency in tissues of infants without peroxisomes (Zellweger syndrome). Nature 1983; 306:69-70.
20. Datta NS, Wilson GN, Hajra AK. Deficiency of enzymes catalyzing the biosynthesis of glycerol-ether lipids in Zellweger syndrome: a new category of metabolic disease involving the absence of peroxisomes. N Engl J Med 1984; 31:1080-1083.
21. Pedersen JI, Gustafsson J. Conversion of 3a,7a,12a-trihydroxy-5b-cholestanoic acid into cholic acid by rat liver peroxisomes. FEBS Lett 1980; 121:345-348.
22. Krisans SK, Thompson SL, Pena LA, Kok E, Javitt NB. Bile acid synthesis in rat liver peroxisomes: metabolism of 26-hydroxycholesterol to 3b-hydroxy-5-cholenoic acid. J Lipid Res 1985; 26:1324-1932.
23. Hanson RF, Szczepanick-van Leeuwen P, Williams GC, Grabowski G, Sharp HL. Defects of bile acid synthesis in Zellweger's syndrome. Science 1979; 203:1107-1108.
24. Keller GA, Barton MC, Shapiro DJ, Singer SJ. 3-Hydroxy-3-methylglutaryl coenzyme A reductase is present in peroxisomes in normal rat liver cells. Proc Natl Acad Sci U S A 1985; 82:770-774.
25. Krisans SK. The role of peroxisomes in cholesterol metabolism. Am J Respir Cell Mol Biol 1992; 7:358-364.
26. Poulos A, Sharp P, Fellenberg AJ, Danks DM. Cerebro-hepato-renal (Zellweger) syndrome, adrenoleukodystrophy and Refsum's disease; plasma changes and skin fibroblast phytanic acid oxidase. Hum Genet 1985; 70:172-177.
27. Singh H, Usher S, Johnson D, Poulos A. A comparative study of straight chain and branched chain fatty acid oxidation in skin fibroblasts from patients with peroxisomal disorders. J Lipid Res 1990; 31:217-225
28. Danks DM, Tippett P, Adams C, Campbell P: Cerebro-hepato-renal syndrome of Zellweger: a report of eight cases with comments upon the incidence, the liver lesion, and a fault in pipecolic acid metabolism. J Pediatr 1975; 86:382-387.
29. Dancis J, Hutzler J. The significance of hyperpipecoliatemia in Zellweger syndrome. Am J Hum Genet 1986; 38:707-711.
30. Gould SG, Keller GA, Subramani S. Identification of a peroxisomal targeting signal at the carboxy terminus of firefly luciferase. J Cell Biol 1987; 105:2923-2931.
31. Swinkels BW, Gould SJ, Bodnar AG, Rachubinski RA, Subramani S. A novel, cleavable peroxisomal targeting signal at the amino-terminus of the rat 3-ketoacyl-CoA thiolase. EMBO J 1991; 10:3255-3262.
32. Distel B, Erdmann R, Gould SJ, Blobel G, Crane DI, Cregg JM, et al. A unified nomenclature for peroxisome biogenesis factors. Cell Biol 1996; 135:1-3.
33. Subramani S. Components involved in peroxisome import, biogenesis, proliferation, turnover, and movement. Physiol Rev 1998; 78:171-188.
34. Reuber BE, Germain-Lee E, Collins CS, Morrell JC, Ameritunga R, Moser HW, et al. Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders. Nat Genet 1997; 17:445-448.
35. Santos MJ, Imanaka T, Shio H, Small GM, Lazarow PB. Peroxisomal membrane ghosts in Zellweger syndrome - aberrant organelle assembly. Science 1988; 239:1536-1538.
36. Brul S, Westerveld A, Strijland A, Wanders PJA, Schram AW, Heymans HSA, et al. Genetic heterogeneity in the cerebrohepatorenal (Zellweger) syndrome and other inherited disorders with a generalized impairment of peroxisomal functions - a study using complementation analysis. J Clin Invest 1988; 81:1710-1715.
37. Roscher AA, Hoefler S, Hoefler G, Paschke E, Paltauf F, Moser A, Moser HW. Genetic and phenotypic heterogeneity in disorders of peroxisome biogenesis - a complementation study involving cell lines from 19 patients. Pediatr Res 1989; 26:67-72.
38. Yajima S, Suzuki T, Shimozawa N, Yamaguchi S, Orii T, Fujiki Y, et al. Complementation study of peroxisome-deficient disorders by immunofluorescence staining and characterization of fused cells. Hum Genet 1992; 88:491-499.
39. Moser A, Rasmussen M, Naidu S, Watkins P, McGuinness M, Hajra A, et al. Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups. J. Pediatr 1995; 125:755-767.
40. Portsteffen H, Beyer A, Becker E, Epplen C, Pawlak A, Kunau WH, Dodt G. Human PEX1 is mutated in complementation group 1 of the peroxisome biogenesis disorders. Nat Genet 1997; 17:449-452.
41. Imamura A, Tamura S, Shimozawa N, Suzuki Y, Zhang Z, Tsukamoto T, et al. Temperature-sensitive mutation in PEX1 moderates the phenotypes of peroxisome deficiency disorders. Hum Mol Genet 1998; 7:2089-2094.
42. Maxwell MA, Nelson PV, Chin SJ, Paton BC, Carey WF, Crane DI. A common PEX1 frameshift mutation in patients with disorders of peroxisome biogenesis correlates with the severe Zellweger syndrome phenotype. Hum Genet 1999; 105:38-44. An important article that differentiates the classic Zellweger's syndrome phenotype from its milder variants at the molecular level.
43. Collins CS, Gould SJ. Identification of a common PEX1 mutation in Zellweger syndrome. Hum Mutat 1999; 14:45-53.
44. Martinez M. Developmental profiles of polyunsaturated fatty acids in the brain of normal infants and patients with peroxisomal diseases: severe deficiency of docosahexaenoic acid in Zellweger's and pseudo-Zellweger's syndromes. In: World review of nutrition and dietetics. Simopoulos AP (editor). Basilea: S. Karger; 1991. pp. 87-102.
45. Theda C, Moser AB, Powers JM, Moser HW. Phospholipids in X-linked adrenoleukodystrophy white matten fatty acid abnormalities before the onset of demyelination. J Neural Sci 1992; 110:195-204.
46. Martinez M. Polyunsaturated fatty acid changes suggesting a new enzymatic defect in Zellweger syndrome. Lipids 1989; 24:261-265.
47. Martinez M. Severe deficiency of docosahexaenoic acid in peroxisomal disorders: a defect of Δ-desaturation? Neurology 1990; 40:1292-1298.
48. Martinez M. Severe changes in polyunsaturated fatty acids in the brain, liver, kidney, and retina in patients with peroxisomal disorders. In: Neurobiology of essential fatty acids. Bazan N. (editor). New York: Plenum; 1992. pp. 347-359.
49. Martinez M. Abnormal profiles of polyunsaturated fatty acids in the brain, liver, kidney and retina of patients with peroxisomal disorders. Brain Res 1992; 583:171-182.
50. Martinez M. Polyunsaturated fatty acids in the developing human brain, erythrocytes and plasma in peroxisomal disease: therapeutic implications. J Inherit Metab Dis 1995; 18 (Suppl. 1):61-75.
51. Martinez M, Mougan I, Roig M, Ballabriga A. Blood polyunsaturated fatty acids in patients with peroxisomal disorders. A multicenter study. Lipids 1994; 29:273-280.
52. Jones CR, Arai T, Rapoport SI. Evidence for the involvement of docosahexaenoic acid in cholinergic stimulated signal transduction at the synapse. Neurochem Res 1997; 22:663-670.
53. Neuringer M, Connor WE, Lin DS, Barstad L, Luck S. Biochemical and functional effects of prenatal and postnatal omega-3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc Natl Acad Sci USA 1986; 83:4021-4025.
54. Martinez M. Treatment with docosahexaenoic acid favorably modifies the fatty acid composition of erythrocytes in peroxisomal patients. In: New developments in fatty acid oxidation. Coates PM, Tanaka K (editors). New York: Wiley-Liss, 1992. pp. 389-397.
55. Martinez M, Pineda M, Vidal R, Martin B. Docosahexaenoic acid - a new therapeutic approach to peroxisomal-disorder patients: experience with two cases. Neurology 1993; 43:1389-1397.
56. Martinez M, Mougan I. Fatty acid composition of brain glycerophospholipids in peroxisomal disorders. Lipids 1999; 34:733-740. This paper reveals the fatty acid composition of plasmalogens in the brain of patients with peroxisomal disorders.
57. Voss A, Reinhart M, Sankarappa S, Sprecher H. The metabolism of 7,10,13,16,19 docosapentaenoic acid to 4,7,10,13,16,19-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J Biol Chem 1991; 266:19995-20000.
58. Sprecher H. An update on the pathways of polyunsaturated fatty acid metabolism. Curr Opin Clin Nutr Metab Care 1999; 2:135-138. An interesting review of the current concepts on the metabolism of long chain polyunsaturated fatty acids.
59. Dry J, Pradalier A, Canny M. Maladie de Refsum: dix ans de régime pauvre en acide phytanique et phytol. Ann Med Interne (Paris) 1982; 133:483-487.
60. Rizzo WB, Leshner RT, Odone A, Dammann AL, Craft DA, Jensen ME, et al. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology 1989; 39:1415-1422.
61. Wilson GN, Holmes RG, Custer J, Lipkowitz JI, Stover J, Datta N, Hajra A. Zellweger syndrome: diagnostic assays, syndrome delineation, and potential therapy. Am J Med Genet 1986; 24:69-82.
62. Setchell KDR, Bragetti P, Zimmer-Nechemias L, Daugherty C, Pelli MA, Vaccaro R, et al. Oral bile acid treatment and the patient with Zellweger syndrome. Hepatology 1992; 15:198-207.
63. Smeitink JMA, Beemer FA, Speel M, Donckerwolcke RAMG, Jakobs C, Wanders RJA, et al. Bone dysplasia associated with phytanic acid accumulation and deficient plasmalogen synthesis: a peroxisomal entity amenable to plasmapheresis. J Inherit Metab Dis 1992; 15:377-380.
64. Bjorkhem I, Blomstrand S, Glaumann H, Strandvik B. Unsuccessful attempts to induce peroxisomes in two cases of Zellweger disease by treatment with clofibrate. Pediatr Res 1985; 19:590-593.
65. Martinez M, Conde C, Ballabriga A. Some chemical aspects of human brain development. II. Phosphoglyceride fatty acids. Pediatr Res 1974; 8:91-102.
66. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr 1992; 120:S129-138.
67. Martinez M, Ballabriga A. A chemical study on the development of the human forebrain and cerebellum during the brain 'growth spurt' period. I. Gangliosides and plasmalogens. Brain Res 1978; 159:351-362.
68. Purpura DP. Morphogenesis of the visual cortex in the preterm infant. In: Growth and development of the brain. Brazier MAB (editor). New York: Raven Press; 1975. pp. 33-49.
69. Martinez M. Myelin lipids in the developing cerebrum, cerebellum, and brain stem of normal and undernourished children. J Neurochem 1982; 39:1684-1692.
70. Martinez M, Mougan I. Fatty acid composition of human brain phospholipids during normal development. J. Neurochem 1998; 71:2528-2533.
71. Dobbing J. Vulnerable periods in developing brain. In: Applied Neurochemistry. Davison AN, Dobbing J (editors). Edinburgh: Blackwell 1968. pp. 287-316.
72. Wiggins RC, Fuller GN. Early postnatal starvation causes lasting hypomyelination. J Neurochem 1978; 30:1231-1237.
73. Martínez M. Docosahexaenoic acid therapy in DHA-deficient patients with disorders of peroxisomal biogenesis. Lipids 1996; 31:S145-152.
74. Martinez M. Docosahexaenoic acid ethyl ester as a treatment for patients with generalized peroxisomal disorders. In Lipids in infant nutrition. Huang YS, Sinclair AJ (editors). Champaign, Illinois: AOCS Press; 1998. pp. 29-38.
75. Martinez M, Vazquez E. MRI evidence that docosahexaenoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology 1998; 51:26-32.
76. Martinez M, Vazquez E, García Silva MT, Manzanares J, Bertran JM, Castelló F, et al. Tratamiento de las enfermedades peroxisomales generalizadas con etil ester del ácido docosahexaenoico. Rev Neurologia 1998; 28:S59-64.
77. Martinez M, Vazquez E, García Silva MT, Manzanares J, Bertran JM, Castelló F, Mougan I. Therapeutical effects of docosahexaenoic acid in patients with generalized peroxisomal disorders. Am J Clin Nutr 2000; 71 (Suppl):376S-385S. This article summarizes the outcome of 7 years of DHA therapy in a small group of patients with generalized peroxisomal disorders, and gives some basic concepts on this new treatment.